- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07479433
Het NAVIGATE-PCI-register: Een nieuwe aanpak voor CT-afgeleide begeleiding vóór stenting om efficiënte PCI te plannen (NAVIGATE-PCI)
Het NAVIGATE-PCI-register: Een nieuwe benadering voor CT-afgeleide begeleiding vóór stenting om efficiënte PCI te plannen
The objective of Heartflow's NAVIGATE-PCI Registry is to collect observational data about the management of patients before and after deployment of Heartflow's PCI Navigator.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Heartflow's NAVIGATE-PCI Registry is a post-market, multi-center, data collection registry assessing confidence in procedure planning, time of procedure, contrast usage during procedure, radiation usage during procedure, invasive imaging (angiographic or other), and resource utilization. Sites will provide retrospective data from patients receiving an elective PCI prior to the deployment of PCI Navigator vs. after deployment and operator training on how to use the information provided by PCI Navigator. Baseline demographic, medical history, procedural, and in-hospital outcome information will be collected following the procedure. No post discharge follow-up data will be collected.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Abby Doctolero
- Telefoonnummer: 650-241-1221
- E-mail: adoctolero@heartflow.com
Studie Contact Back-up
- Naam: Sarah Mullen
- Telefoonnummer: 650-241-1221
- E-mail: smullen@heartflow.com
Studie Locaties
-
-
California
-
Palo Alto, California, Verenigde Staten, 94304
- Werving
- Stanford Medical Center
-
Contact:
- Juyong Brian Kim, MD
- Telefoonnummer: 650-721-7119
- E-mail: kimjb@stanford.edu
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33136
- Werving
- University of Miami
-
Contact:
- Yiannis Chatzizisis, MD
- Telefoonnummer: 305-243-4950
- E-mail: ychatzizisis@med.miami.edu
-
Naples, Florida, Verenigde Staten, 34102
- Werving
- Naples Comprehensive Health
-
Contact:
- Adam Frank, MD
- Telefoonnummer: 2396248395
- E-mail: Adam.Frank@nchmd.org
-
Tampa, Florida, Verenigde Staten, 33606
- Werving
- University of South Florida
-
Contact:
- Hiram Bezerra, MD
- Telefoonnummer: 813-395-2194
- E-mail: hbezerra@tgh.org
-
-
Georgia
-
Marietta, Georgia, Verenigde Staten, 30060
- Werving
- Wellstar Health System
-
Contact:
- Frank Corrigan, MD
- Telefoonnummer: 470-793-4034
- E-mail: Frank.Corrigan@wellstar.org
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60657
- Werving
- Advocate Illinois Masonic Medical Center
-
Contact:
- Joaquin Gonzalez, MD
- Telefoonnummer: 630.730.6343
- E-mail: joaquin.gonzalez@aah.org
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Northwestern Memorial Hospital
-
Contact:
- Daniel Schimmel, MD
- Telefoonnummer: 312.695.4067
- E-mail: dschimme@nm.org
-
Glenview, Illinois, Verenigde Staten, 60026
- Werving
- Endeavor Health
-
Contact:
- Amit Pursnani, MD
- Telefoonnummer: 847-503-6444
- E-mail: amit.pursnani@endeavorhealth.org
-
Urbana, Illinois, Verenigde Staten, 61801
- Werving
- Carle Foundation Hospital
-
Contact:
- Issam Moussa, MD
- Telefoonnummer: 217-326-0102
- E-mail: Issam.Moussa@carle.com
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40202
- Werving
- Norton Hospital
-
Contact:
- Daniel Stewart, MD
- Telefoonnummer: 502-891-8631
- E-mail: daniel.stewart@nortonhealthcare.org
-
-
Michigan
-
Royal Oak, Michigan, Verenigde Staten, 48073
- Werving
- Corewell Health William Beaumont University Hospital
-
Contact:
- Ryan Madder, MD
- Telefoonnummer: 248.551.6679
- E-mail: Ryan.Madder@corewellhealth.org
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Werving
- Allina Health Minneapolis Heart Institute
-
Contact:
- Yader Sandoval, MD
- Telefoonnummer: 612.863.4768
- E-mail: Yader.Sandoval@allina.com
-
Saint Cloud, Minnesota, Verenigde Staten, 56303
- Werving
- CentraCare - St. Cloud Hospital
-
Contact:
- Juliette Power, MD
- Telefoonnummer: 320-251-2700
- E-mail: Juliette.Power@centracare.com
-
-
New Jersey
-
Camden, New Jersey, Verenigde Staten, 08103
- Werving
- Virtua Our Lady of Lourdes Hospital
-
Contact:
- Luai Tabaza, MD
- Telefoonnummer: 856-355-1225
- E-mail: LTABAZA@virtua.org
-
-
New York
-
Roslyn, New York, Verenigde Staten, 11576
- Werving
- St. Francis Hospital and Heart Center
-
Contact:
- Evan Shlofmitz, DO
- Telefoonnummer: 516-629-2052
- E-mail: Evan.Shlofmitz@chsli.org
-
-
North Carolina
-
Greensboro, North Carolina, Verenigde Staten, 27401
- Werving
- Cone Health Moses Cone Hospital
-
Contact:
- Muhammad Arida, MD
- Telefoonnummer: 336-832-3795
- E-mail: Muhammad.Arida@conehealth.com
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Werving
- Oregon Health & Science University
-
Contact:
- Maros Ferencik, MD
- Telefoonnummer: 503-418-2696
- E-mail: ferencik@ohsu.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Werving
- Allegheny General Hospital
-
Contact:
- Ramzi Khalil, MD
- Telefoonnummer: (412) 359-6908
- E-mail: ramzi.khalil@ahn.org
-
Wynnewood, Pennsylvania, Verenigde Staten, 19096
- Werving
- Lankenau Medical Center
-
Contact:
- Mara Caroline, MD
- Telefoonnummer: 484.476.8579
- E-mail: CarolineM@mlhs.org
-
York, Pennsylvania, Verenigde Staten, 17403
- Werving
- WellSpan York Hospital
-
Contact:
- Paul Tolerico, MD
- Telefoonnummer: 717-356-5159
- E-mail: ptolerico@wellspan.org
-
-
South Carolina
-
Columbia, South Carolina, Verenigde Staten, 29203
- Werving
- Prisma Health Richland Hospital
-
Contact:
- Gopi Shah, MD
- Telefoonnummer: 803-434-3800
- E-mail: gopi.shah@prismahealth.org
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22908
- Werving
- UVA Health University Medical Center
-
Contact:
- Rajan Patel, MD
- Telefoonnummer: 434-982-1058
- E-mail: RAP8B@uvahealth.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Deidentified data will be collected for all patients included in the registry who had a CCTA with acceptable image quality prior to elective PCI and are included by the site in the registry. Patients with prior CABG or patients with intervention planned in a previously stented vessel territory are excluded.
Beschrijving
Inclusion Criteria (all must be present):
- CCTA completed ≤90 days prior to elective PCI with acceptable image quality according to Heartflow's image quality requirements
- Referred for elective PCI
- Clinically stable without symptoms suggestive of acute coronary syndrome (ACS) at the time of the intervention
Exclusion Criteria (all must be present):
- ED presentation (at the time of the referral for PCI)
- Previous coronary artery bypass graft (CABG)
- Planned intervention in a previously stented vessel territory
- Acute chest pain (in patients who have not been ruled out for ACS)
- Participating in a conflicting study being undertaken during the PCI
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: CROSS_SECTIONAL
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Group 1: No PCI Navigator
This group includes consecutive patients who have undergone a CCTA a maximum of 90 days prior to an elective PCI at the study site; the CCTA is not required to have been used in procedural planning but must have acceptable image quality according to Heartflow's image quality requirements |
|
|
Group 2: Intraprocedural PCI Planning
This group includes patients who had a CCTA and a referral for elective PCI following the introduction of the PCI Navigator at the study site. The PCI should be performed no more than 90 days following the CCTA. Interventionalists will document their procedural plan after initial invasive angiographic images are reviewed but before reviewing the information provided by the PCI Navigator, and then again after reviewing the information provided by the PCI Navigator. Usage of invasive imaging following review of the PCI Navigator is at the discretion of the interventionalist. |
Heartflow PCI Navigator is the only integrated, AI-driven PCI planning tool that gives interventional cardiologists a patient-specific 3D model, detailing anatomy, plaque composition, and lesion-specific physiology, all aligned to optimize potential stent placement. PCI Navigator delivers a streamlined view of essential information for cath lab decision-making by integrating all relevant measurements, including IVUS-like and FFR-like pullback visualizations, into one seamless experience, which typically requires significant time and effort to obtain in the cath lab. |
|
Group 3: Preprocedural Planning
This group includes patients who had a CCTA and a referral for elective PCI following the introduction of the PCI Navigator at the study site. The PCI should be performed no more than 90 days following the CCTA. Interventionalists will document their procedural plan before reviewing the information provided by the PCI Navigator and prior to initial invasive angiographic imaging, and then again after reviewing the information provided by the PCI Navigator. Usage of angiographic and other invasive imaging following review of the PCI Navigator is at the discretion of the interventionalist. |
Heartflow PCI Navigator is the only integrated, AI-driven PCI planning tool that gives interventional cardiologists a patient-specific 3D model, detailing anatomy, plaque composition, and lesion-specific physiology, all aligned to optimize potential stent placement. PCI Navigator delivers a streamlined view of essential information for cath lab decision-making by integrating all relevant measurements, including IVUS-like and FFR-like pullback visualizations, into one seamless experience, which typically requires significant time and effort to obtain in the cath lab. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Primary Endpoint
Tijdsspanne: 90 Days
|
The primary endpoint will be assessed only in Group 2 and is a change in procedural plan following review of the information provided by PCI Navigator compared to procedural plan with angiographic imaging alone. The primary endpoint will be measured by calculating the percentage of patients in whom a change of plan was documented following review of the PCI Navigator tool compared to the plan documented prior to using the tool. |
90 Days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Veranderingen in vertrouwen met en zonder PCI Navigator (beoordeeld in Groep 2 en 3 als twee afzonderlijke analyses)
Tijdsspanne: 90 dagen voor Groep 2, 18 maanden voor Groep 3
|
90 dagen voor Groep 2, 18 maanden voor Groep 3
|
|
Verandering in proceduretijd met en zonder PCI Navigator
Tijdsspanne: 90 dagen
|
90 dagen
|
|
Verandering in contrastgebruik met en zonder PCI Navigator
Tijdsspanne: 90 dagen
|
90 dagen
|
|
Verandering in stralingsgebruik tijdens PCI met en zonder PCI Navigator
Tijdsspanne: 90 dagen
|
90 dagen
|
|
Verandering in invasieve beeldvorming (angiografisch of anders) met en zonder PCI Navigator
Tijdsspanne: 90 dagen
|
90 dagen
|
|
Verandering in het gebruik van middelen met en zonder PCI Navigator
Tijdsspanne: 90 dagen
|
90 dagen
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Exploratory and Safety Endpoint
Tijdsspanne: 5 years
|
Perform all endpoint analyses with a comparison of male vs. female as an added variable |
5 years
|
|
Exploratory and Safety Endpoint
Tijdsspanne: 5 years
|
Procedural complications and in-hospital outcomes |
5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Ziad Ali, MD, DPhil, St. Francis Hospital & Heart Center Columbia University
- Hoofdonderzoeker: Todd C. Villines, MD, University of Virginia
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CP-911-001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .